{"altmetric_id":3461391,"counts":{"readers":{"mendeley":54,"citeulike":0,"connotea":0},"total":{"posts_count":2},"wikipedia":{"unique_users_count":2,"unique_users":["en:12198134","en:32684479"],"posts_count":2}},"citation":{"altmetric_jid":"4f6fa4e93cf058f61000245a","authors":["Attard, Gerhardt","Belldegrun, Arie S.","De Bono, Johann S."],"doi":"10.1111\/j.1464-410x.2005.05821.x","first_seen_on":"2015-02-10T16:39:32+00:00","issns":["1464-410X","1464-4096"],"journal":"British Journal of Urology","last_mentioned_on":1339463866,"links":["http:\/\/dx.doi.org\/10.1111\/j.1464-410X.2005.05821.x","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16287438"],"pdf_url":"http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2005.05821.x\/pdf","pubdate":"2005-09-29T00:00:00+00:00","publisher":"Blackwell Science Ltd","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"title":"Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/selective-blockade-androgenic-steroid-synthesis-novel-lyase-inhibitors-therapeutic-strategy-treating"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":3619417,"mean":4.9286052998637,"rank":815691,"this_scored_higher_than_pct":62,"this_scored_higher_than":2280019,"rank_type":"exact","sample_size":3619417,"percentile":62},"similar_age_3m":{"total_number_of_other_articles":93583,"mean":7.2441967258661,"rank":23733,"this_scored_higher_than_pct":73,"this_scored_higher_than":68765,"rank_type":"exact","sample_size":93583,"percentile":73},"this_journal":{"total_number_of_other_articles":2027,"mean":4.9205765054294,"rank":510,"this_scored_higher_than_pct":58,"this_scored_higher_than":1191,"rank_type":"exact","sample_size":2027,"percentile":58},"similar_age_this_journal_3m":{"total_number_of_other_articles":23,"mean":54.574181818182,"rank":10,"this_scored_higher_than_pct":52,"this_scored_higher_than":12,"rank_type":"exact","sample_size":23,"percentile":52}}},"demographics":{"users":{"mendeley":{"by_status":{"Professor > Associate Professor":2,"Researcher":12,"Student  > Doctoral Student":2,"Student  > Ph. D. Student":10,"Student  > Postgraduate":1,"Student  > Master":11,"Other":5,"Student  > Bachelor":8,"Lecturer":1,"Lecturer > Senior Lecturer":2},"by_discipline":{"Engineering":1,"Medicine and Dentistry":27,"Chemistry":7,"Agricultural and Biological Sciences":14,"Biochemistry, Genetics and Molecular Biology":4,"Unspecified":1}}},"geo":{"mendeley":{"NL":2,"TR":1,"BR":1,"GB":1,"PT":1,"DE":1}}},"posts":{"wikipedia":[{"title":"Abiraterone","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=143885623#altmetric_citation_0","license":"public","citation_ids":[3461391],"posted_on":"2007-07-11T03:25:33+00:00","summary":"Abiraterone is a drug used in combination with prednisone in metastatic castration-resistant prostate cancer (formerly hormone-resistant or hormone-refractory prostate cancer) -- i.e., prostate cancer not responding to androgen deprivation or treatment wit","page_url":"http:\/\/en.wikipedia.org\/?curid=12198134","wiki_lang":"en","author":{"name":"Uthbrian","url":"http:\/\/en.wikipedia.org\/wiki\/User:Uthbrian"}},{"title":"Orteronel","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=497151511#altmetric_citation_1","license":"public","citation_ids":[3461391],"posted_on":"2012-06-12T01:17:46+00:00","summary":"Orteronel (TAK-700) is an antiandrogen that was being developed for the treatment of cancer by Takeda Pharmaceutical Company in conjunction with Millennium Pharmaceuticals.","page_url":"http:\/\/en.wikipedia.org\/?curid=32684479","wiki_lang":"en","author":{"name":"Seuraza","url":"http:\/\/en.wikipedia.org\/wiki\/User:Seuraza"}}]}}